Federico Pessina1, Pierina Navarria2, Luca Cozzi3, Anna Maria Ascolese2, Giulia Maggi2, Marco Rossi1, Marco Riva1, Marta Scorsetti4, Lorenzo Bello1. 1. Department of Neurosurgical Oncology, Humanitas Cancer Center and Research Hospital, Rozzano, Milan, Italy. 2. Department of Radiotherapy and Radiosurgery, Humanitas Cancer Center and Research Hospital, Rozzano, Milan, Italy. 3. Department of Radiotherapy and Radiosurgery, Humanitas Cancer Center and Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy. Electronic address: luca.cozzi@humanitas.it. 4. Department of Radiotherapy and Radiosurgery, Humanitas Cancer Center and Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy.
Abstract
OBJECTIVE: The aim of this study was to evaluate the safety and the feasibility of surgery for single large brain metastases. METHODS: This retrospective study included 69 patients. All received a "supramarginal resection" according to functional boundaries, defined as a microsurgical excision with an extension larger at least 5 mm greater than the enhancing T1-weighted magnetic resonance imaging (MRI) sequence borders with dural attachment radicalization. Hypofractionated stereotactic radiosurgery on the tumor bed, using 30 Gy in 3 fractions, was performed within 1 month after surgery. Clinical outcome was evaluated at 30 days postoperative and by MRI performed every 3 months. The appearance of postoperative neurologic deficits, local control (LC), brain distant progression (BDP), and overall survival were evaluated. RESULTS: Clinical remission of symptomatology was obtained in 90.5% of patients. None of them had new neurologic deficits or worsening of preoperative functional status. No major complications or cerebrospinal fluid leakage occurred. No residual tumor was detected on postoperative MRI. The median follow-up was 24 months (range 4-33 months). The 1- to 2-year LC was 100%. Twenty-four (29% of) patients had new BDP, and 75% had extracranial progression. The median 1- to 2-year overall survival was 24 months, 91.3% and 73%. At the last observation time, 15 patients (21.7%) were dead and 54 patients (78.3%) were alive. CONCLUSION: Supramarginal resection along with dural attachment radicalization have proved to be safe and effective for selected patients with single large brain metastases.
OBJECTIVE: The aim of this study was to evaluate the safety and the feasibility of surgery for single large brain metastases. METHODS: This retrospective study included 69 patients. All received a "supramarginal resection" according to functional boundaries, defined as a microsurgical excision with an extension larger at least 5 mm greater than the enhancing T1-weighted magnetic resonance imaging (MRI) sequence borders with dural attachment radicalization. Hypofractionated stereotactic radiosurgery on the tumor bed, using 30 Gy in 3 fractions, was performed within 1 month after surgery. Clinical outcome was evaluated at 30 days postoperative and by MRI performed every 3 months. The appearance of postoperative neurologic deficits, local control (LC), brain distant progression (BDP), and overall survival were evaluated. RESULTS: Clinical remission of symptomatology was obtained in 90.5% of patients. None of them had new neurologic deficits or worsening of preoperative functional status. No major complications or cerebrospinal fluid leakage occurred. No residual tumor was detected on postoperative MRI. The median follow-up was 24 months (range 4-33 months). The 1- to 2-year LC was 100%. Twenty-four (29% of) patients had new BDP, and 75% had extracranial progression. The median 1- to 2-year overall survival was 24 months, 91.3% and 73%. At the last observation time, 15 patients (21.7%) were dead and 54 patients (78.3%) were alive. CONCLUSION: Supramarginal resection along with dural attachment radicalization have proved to be safe and effective for selected patients with single large brain metastases.
Authors: Johannes Kerschbaumer; Aleksandrs Krigers; Matthias Demetz; Daniel Pinggera; Julia Klingenschmid; Nadine Pichler; Claudius Thomé; Christian F Freyschlag Journal: J Neurooncol Date: 2022-04-13 Impact factor: 4.506
Authors: Andrew Keller; Rahim Ismail; Peter S Potrebko; Julie Pepe; Meiling Wu; Kunal Saigal; Matthew Biagioli; Ravi Shridhar; Robert Holloway; Melvin Field; Nikhil G Rao Journal: Cureus Date: 2016-12-31
Authors: Eduardo E Lovo; Leonel B Torres; Fidel J Campos; Victor E Caceros; Kaory E Barahona; Mario H Minervini; William A Reyes Journal: Cureus Date: 2019-08-24
Authors: Martin A Proescholdt; Petra Schödel; Christian Doenitz; Tobias Pukrop; Julius Höhne; Nils Ole Schmidt; Karl-Michael Schebesch Journal: Cancers (Basel) Date: 2021-03-31 Impact factor: 6.639